Literature DB >> 7889303

Antimuscarinic action of liriodenine, isolated from Fissistigma glaucescens, in canine tracheal smooth muscle.

C H Lin1, C M Yang, F N Ko, Y C Wu, C M Teng.   

Abstract

1. The antimuscarinic properties of liriodenine, isolated from Fissistigma glaucescens, were compared with methoctramine (cardioselective M2 antagonist) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, smooth muscle selective M3 antagonist) by radioligand binding tests, functional tests and measurements of second messenger generation in canine cultured tracheal smooth muscle cells. 2. Liriodenine, pirenzepine, methoctramine and 4-DAMP displaced [3H]-N-methyl scopolamine ([3H]-NMS) binding in a concentration-dependent manner with Ki values of 2.2 +/- 0.4 x 10(-6), 3.3 +/- 0.7 x 10(-7), 8.9 +/- 2.3 x 10(-8) and 2.3 +/- 0.6 x 10(-9) M, respectively. The curves for competitive inhibition of [3H]-NMS with liriodenine, methoctramine and 4-DAMP were best fitted according to a two site model of binding, but pirenzepine was best fitted according to a model with one site. 3. Liriodenine and 4-DAMP displayed a high affinity for blocking tracheal contraction (pKB = 5.9 and 9.1, respectively) and inositol phosphate formation (pKB = 6.0 and 8.9, respectively), but a low affinity for antagonism of cyclic AMP inhibition (pKB = 4.7 and 7.8, respectively). 4. Methoctramine blocked cyclic AMP inhibition with a high affinity (pKB = 7.4), but it antagonized tracheal contraction and inositol phosphate formation with a low affinity (pKB = 6.1 and 6.0, respectively). 5. In conclusion, both M2 and M3 muscarinic receptor subtypes coexist in canine tracheal smooth muscle and are coupled to the inhibition of cyclic AMP formation and phosphoinositide breakdown, respectively. The antimuscarinic characteristics of liriodenine are similar to those of 4-DAMP. It may act as a selective M3 receptor antagonist in canine tracheal smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889303      PMCID: PMC1510520          DOI: 10.1111/j.1476-5381.1994.tb17161.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist.

Authors:  A Giachetti; R Micheletti; E Montagna
Journal:  Life Sci       Date:  1986-05-05       Impact factor: 5.037

2.  Muscarinic receptor heterogeneity in rat central nervous system. I. Binding of four selective antagonists to three muscarinic receptor subclasses: a comparison with M2 cardiac muscarinic receptors of the C type.

Authors:  M Waelbroeck; M Gillard; P Robberecht; J Christophe
Journal:  Mol Pharmacol       Date:  1987-07       Impact factor: 4.436

3.  Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors.

Authors:  H N Doods; M J Mathy; D Davidesko; K J van Charldorp; A de Jonge; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

4.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

5.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization.

Authors:  R Hammer; A Giachetti
Journal:  Life Sci       Date:  1982-12-27       Impact factor: 5.037

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism.

Authors:  J H Brown; S L Brown
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

8.  A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.

Authors:  M Watson; H I Yamamura; W R Roeske
Journal:  Life Sci       Date:  1983-06-27       Impact factor: 5.037

9.  Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs.

Authors:  C H Lin; G J Chang; M J Su; Y C Wu; C M Teng; F N Ko
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

10.  A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes.

Authors:  A M Gown; A M Vogel; D Gordon; P L Lu
Journal:  J Cell Biol       Date:  1985-03       Impact factor: 10.539

View more
  3 in total

1.  Screening an In-House Isoquinoline Alkaloids Library for New Blockers of Voltage-Gated Na+ Channels Using Voltage Sensor Fluorescent Probes: Hits and Biases.

Authors:  Quentin Coquerel; Claire Legendre; Jacinthe Frangieh; Stephan De Waard; Jérôme Montnach; Leos Cmarko; Joseph Khoury; Charifat Said Hassane; Dimitri Bréard; Benjamin Siegler; Ziad Fajloun; Harold De Pomyers; Kamel Mabrouk; Norbert Weiss; Daniel Henrion; Pascal Richomme; César Mattei; Michel De Waard; Anne-Marie Le Ray; Christian Legros
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

2.  Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens.

Authors:  G J Chang; M H Wu; Y C Wu; M J Su
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 3.  Natural Antispasmodics: Source, Stereochemical Configuration, and Biological Activity.

Authors:  Edith Fabiola Martínez-Pérez; Zaida N Juárez; Luis R Hernández; Horacio Bach
Journal:  Biomed Res Int       Date:  2018-10-08       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.